Proteomic profiling of brain‐ and biofluid‐derived EVs has uncovered specific biomarkers and signaling pathways, ranging from tau and α‐synuclein in AD and PD to mutant SOD1 in ALS and complement activation in stroke and TBI. This evidence concerns the gene SOD1 and Alzheimer disease.